Clinical trial
An ITAlian Observational, Multicenter, 12-month, Single-arm Study to Evaluate the Effectiveness and Safety of Treatment With Ofatumumab (Kesimpta®) in a pOpulation of RRMS Patients in a Real-world Setting - the ITAKOS Study
NCT06345157 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An ITAlian Observational, Multicenter, 12-month, Single-arm Study to Evaluate the Effectiveness and Safety of Treatment With Ofatumumab (Kesimpta®) in a pOpulation of RRMS Patients in a Real-world Setting - the ITAKOS Study
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Observational
- Overall status
- Active, not recruiting
- Start date
- July 30, 2024
- Completion date
- June 30, 2026
- Enrollment
- 379 (actual)
- Sites
- 31
Conditions
As the registry lists them; a condition with its own page is linked.